Novartis takes legal action over trusts’ advice to use bevacizumab for wet AMD

BMJ 2012; 344 doi: http://dx.doi.org/10.1136/bmj.e2959 (Published 24 April 2012)
Cite this as: BMJ 2012;344:e2959

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Ingrid Torjesen
  1. 1London

The drug company Novartis is taking a primary care trust cluster on the south coast of England to court over its decision to give NHS ophthalmologists the option to use the cheaper bevacizumab (marketed as Avastin) for wet age related macular degeneration (AMD) rather than the considerably more expensive ranibizumab (Lucentis).

Bevacizumab and ranibizumab are derived from the same antibody and work by blocking vascular endothelial growth factor. In the United Kingdom they are both marketed by Novartis. Ranibizumab costs £890 (€1090; $1440) a dose, is licensed for injection into the eye specifically to treat macular degeneration, and has been recommended by the National Institute for Health and Clinical Excellence (NICE) for the treatment of wet AMD. Avastin is licensed for treating cancer and costs between £50 and £100 a dose.

In September last year the board of the Southampton, Hampshire, Isle of Wight, and Portsmouth primary care trust (PCT) cluster agreed to fund bevacizumab to treat wet AMD by NHS ophthalmologists to save money. The cluster estimated that a switch could save £5m a year. Novartis has asked …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL